Filgotinib

• Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID) Not authorised
  2022-502968-20-01 Phase II 1 country University Medical Center Utrecht
• FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial Pending
  2024-514964-24-00 Phase III 1 country University Hospital Of Clermont-Ferrand
• Filgotinib bridging in newly diagnosed rheumatoid arthritis patients (FAST RA trial); A pragmatic randomized controlled non-inferiority low … Pending
  2024-517112-30-00 Phase IV 1 country Medisch Spectrum Twente
• The effect of Janus Kinase inhibitors on the heart in Rheumatoid Arthritis Pending
  2025-520710-58-00 Phase IV 1 country Reade revalidatie & reumatologie centrum te Amsterdam
• The OASE study Pending
  2026-525221-21-01 Phase IV 1 country Aalborg University Hospital
• STOP - Safety and efficacy of a STOPping strategy versus classical maintenance dose of JAK inhibitors in deep remission patients with ulcera… Pending
  2026-525643-32-00 Phase IV 1 country Centre Hospitalier Regional De Marseille
• Safety, tolerability, pharmacokinetics, and efficacy of filgotinib for the treatment of polyarticular-course juvenile idiopathic arthritis i… Recruiting
  2024-511593-70-00 Phase III 10 countries Alfasigma S.p.A.
• A study evaluating the effects of filgotinib in children and teenagers with ulcerative colitis Recruiting
  2024-511458-32-00 Phase III 12 countries Alfasigma S.p.A.
• A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting
  2022-501354-10-01 Phase III 15 countries Alfasigma S.p.A.
• Open-label extension study with filgotinib in children with juvenile idiopathic arthritis. Recruiting
  2025-523239-21-00 Phase III 2 countries Alfasigma S.p.A.
• Characterization of the immune response in immunosuppressed patients with rheumatic diseases, including to the recombinant zoster vaccine Recruiting
  2024-518190-34-00 Phase IV 1 country Centre Hospitalier Universitaire De Toulouse
• REDO-JAK: Dose REDuction Of JAnus Kinase inhibitors in patients with inflammatory rheumatic diseases Recruiting
  2025-520757-36-00 Phase IV 1 country Sint Maartenskliniek Stichting
• JAK inhibitor dose TAPering strategy study in low disease activity rheumatoid arthritis patients. Recruiting
  2023-509788-25-00 Phase IV 1 country Centre Hospitalier Universitaire De Toulouse
• Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID) Recruiting
  2022-502968-20-02 Phase II 1 country University Medical Center Utrecht
• RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASAL… Recruiting
  2024-516704-41-00 Phase III/IV 1 country Les Hopitaux Universitaires De Strasbourg
• Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient's as well as an economic point… Ended
  2024-511530-12-01 Phase IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis Ended
  2024-516199-14-00 Phase III 1 country Alfasigma S.p.A.
• Study to measure filgotinib in the blood of children and teenagers with arthritis taking filgotinib-GLPG0634-CL-131 Ended
  2023-505844-21-00 Phase I (Other) 4 countries Alfasigma S.p.A.
• A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis Ended
  2024-513919-27-00 Phase III 3 countries Alfasigma S.p.A.

Showing 1–19 of 19 trials